Drug development has long faced significant challenges with prolonged development cycles (10-15 years) and low success rates in penetrating markets. Bringing a new drug from its discovery phase to a safe, effective, and FDA-approved treatment involves a number of important checkpoints and typically require multi-hundred-million-dollar investments. Even so, only 1 in 5,000 drug candidates reach the commercial market, as pharmaceutical companies face greater possibilities of generating insufficient returns on their investments.

To account for the economic benefits and risks of developing a new drug, traditional pharmaceutical companies are left with seeking ONLY large addressable markets AND charging high premiums for the newly-developed interventions in order to recover their spending in R&D, regulations, and marketing. Naturally, USA and EU, with their large population sizes and high levels of medical expenditures, become the primary markets for all new medical innovations.

Using the unique and innovative fundraising strategy of an initial coin offering (ICO), ABC can meaningfully address such problems of market limitations and high drug costs caused by the pursuit of return of investment. More importantly, the TAP will grant participants exclusive and guaranteed access to treatments and diagnostics in early stage of market release.